Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Stage, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19

NCT04458298 is registered in ClinicalTrials.gov with Ashvattha Therapeutics, Inc. as lead sponsor.

NCT NCT04458298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04458298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Stage, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19
Lead sponsor
Ashvattha Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 11, 2020
Completion date
August 12, 2022
Enrollment
28 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19